Chronic Progressive Neurodegeneration in a Transgenic Mouse Model of Prion Disease by Nina Fainstein et al.
ORIGINAL RESEARCH
published: 11 November 2016
doi: 10.3389/fnins.2016.00510
Frontiers in Neuroscience | www.frontiersin.org 1 November 2016 | Volume 10 | Article 510
Edited by:
Jean-Michel Verdier,
Ecole Pratique des Hautes Etudes,
France
Reviewed by:
M. Heather West Greenlee,
Iowa State University, USA
Clevio Nobrega,
University of the Algarve, Portugal
*Correspondence:
Tamir Ben-Hur
tamir@hadassah.org.il
†
These authors have contributed
equally to this work.
Specialty section:
This article was submitted to
Neurodegeneration,
a section of the journal
Frontiers in Neuroscience
Received: 14 June 2016
Accepted: 24 October 2016
Published: 11 November 2016
Citation:
Fainstein N, Dori D, Frid K, Fritz AT,
Shapiro I, Gabizon R and Ben-Hur T
(2016) Chronic Progressive
Neurodegeneration in a Transgenic
Mouse Model of Prion Disease.
Front. Neurosci. 10:510.
doi: 10.3389/fnins.2016.00510
Chronic Progressive
Neurodegeneration in a Transgenic
Mouse Model of Prion Disease
Nina Fainstein †, Dvir Dori †, Kati Frid, Alexa T. Fritz, Ilona Shapiro, Ruth Gabizon and
Tamir Ben-Hur *
Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah – Hebrew University Medical
Center, Jerusalem, Israel
Neurodegenerative diseases present pathologically with progressive structural
destruction of neurons and accumulation of mis-folded proteins specific for each
condition leading to brain atrophy and functional disability. Many animal models
exert deposition of pathogenic proteins without an accompanying neurodegeneration
pattern. The lack of a comprehensive model hinders efforts to develop treatment. We
performed longitudinal quantification of cellular, neuronal and synaptic density, as well
as of neurogenesis in brains of mice mimicking for genetic Creutzfeldt-Jacob disease
as compared to age-matched wild-type mice. Mice exhibited a neurodegenerative
process of progressive reduction in cortical neurons and synapses starting at age of
4–6 months, in accord with neurologic disability. This was accompanied by significant
decrease in subventricular/subependymal zone neurogenesis. Although increased
hippocampal neurogenesis was detected in mice, a neurodegenerative process of CA1
and CA3 regions associated with impaired hippocampal-dependent memory function
was observed. In conclusion, mice exhibit pathological neurodegeneration concomitant
with neurological disease progression, indicating these mice can serve as a model for
neurodegenerative diseases.
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INTRODUCTION
Neurodegenerative diseases are late-onset fatal disorders that affect large numbers of individuals
(Hamacher and Marcus, 2007). In addition to the progressive death of neurons, neurodegenerative
diseases cause accumulation of aberrantly-folded “key” disease proteins (Morales and Green, 2009;
Aguzzi and O’Connor, 2010; Perry et al., 2012), which individually characterize each of these
conditions, including amyloid β in Alzheimer’s disease (AD), α synuclein in Parkinson’s disease
(PD) and prion protein (PrPSc) in prion diseases such as Creutzfeldt-Jakob disease (CJD) (Prusiner,
1982; Olanow and Prusiner, 2009). These aggregates are considered hallmarks of neurodegenerative
diseases (Ashe and Aguzzi, 2013; Prusiner, 2013). The mechanisms which result in abnormal
proteins deposition and neurodegeneration are not entirely clear. Several common mechanisms of
injury have been described in various neurodegenerative diseases, including prion diseases. These
include the toxic effects of misfolded proteins (Doyle et al., 2011), oxidative stress and lipid and
protein oxidation (Grimm et al., 2011), microglial activation (Heneka et al., 2014), activation of
autophagy by intracellular protein aggregates (Yang et al., 2013), and dysfunction of other cellular
functions, such as proteasome and mitochondria (Figueiredo-Pereira et al., 2014).
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The animal models which were constructed for these
conditions demonstrate accumulation of aberrantly-folded
proteins. However, they are devoid of other pathological signs
of neurodegeneration such as progressive neuronal loss and
severe clinical features. In this project, we studied the presence
of the neurodegenerative process in a mouse model of genetic
CJD.
TGMHU2ME199K/KO: A TRANSGENIC
MOUSE MODEL OF FAMILIAL PRION
DISEASE
Prion diseases are a group of neurodegenerative diseases
associated with deposition of abnormal prion protein in the
brain. Pathologically, there is neuronal loss and atrophy in
the cortex and deep-seated nuclei, which is associated with
diffuse and plaque-like deposition of PrP, and accumulation of
brain vacuoles surrounded by PrP deposits(Puoti et al., 1999;
Gambetti et al., 2003). The most common genetic form of the
disease (familial Creutzfeldt-Jakob disease, fCJD) is caused by a
point mutation in codon 200 of the PrP gene, replacing Lysine
(K) for glutamate (E) (Hsiao et al., 1991). The murine PrP
gene differs from its human counterpart by 28 amino acids. A
human / murine chimeric gene has been constructed which is
mostly murine, but contains nine amino acids from the human
gene between codons 96 and 167 (Telling et al., 1994). Unlike
Tg mice expressing the human PrP gene, animals expressing
chimeric mouse human PrP can be easily infected with human
prions (Telling et al., 1995). Insertion of the E to K mutation
at the relevant position (codon 199, representing the human
E200K mutation) led to the generation of a transgenic mouse
line (TgMHu2ME199K/KO). These mice suffer from progressive
neurological symptoms as early as 5–6 month of age and
deteriorate to a terminal condition several months thereafter,
concomitant with the accumulation of a truncated form of
protein kinase-resistant PrP (Kovacs et al., 2010; Friedman-Levi
et al., 2011, 2013). TgMHu2ME199K/KO mice exhibit typical
pathological features of human CJD, such as gliosis and lipid
oxidation, and have already been used successfully to test the
activity of a candidate reagent (Mizrahi et al., 2014)
In this project, we characterized the neurodegenerative
pathological features of TgMHu2ME199K/KO mice in relation
to age and clinical disease progression. We found a facilitated
progressive reduction in cortical neurons and synapses as
compared to normal aging, starting at age 4–6 months, according
with neurologic disability. There was significant decrease in
neurogenesis in the subventricular / subependymal zone. A
similar progressive loss of neurons in the CA1 and CA3 regions
of the hippocampus was associated with impaired hippocampal-
dependent memory functions. Interestingly, there was increased
hippocampal neurogenesis in TgMHu2ME199K/KO mice prior
to decline in memory functions. Therefore, we believe the
TgMHu2ME199K/KO model can serve both to study the
neurodegenerative pathways as well as to test neuroprotective
drugs and regenerative therapies that may be relevant to this and
other neurodegenerative conditions.
METHODS
Animals
Twenty-five C57BL/6 mice and 23 TgMHu2ME199K/KO
mice of murine PrPC knockout C57BL/6 mouse background
(Friedman-Levi et al., 2011) were used in this study. All
mice were grown under Specific-pathogen free conditions.
Animal experimentation was approved by the institutional ethics
committee.
Clinical Scoring and Evaluation of
Hippocampus-Dependent Memory
Mice were scored for disease severity and progression according
to a scale of clinical signs designed by us to fit the clinical
symptoms observed (Friedman-Levi et al., 2011) in the Tg mice.
Hind limb mild weakness = 1, Hind limb partial paralysis =
2, Full paralysis in one limb = 3, Full hind limb paralysis = 4,
Death = 5. Hind limb weakness was first evaluated by closely
watching the mouse walking on a flat surface, looking for signs
of abnormal limb posture or abnormal walking pattern (high or
low gait, leg-dragging). Next, mice were tested for their ability
to walk in a straight line on a 3 cm beam and maintain balance.
Finally mice were lifted by their tail to check for leg-clasping. Full
paralysis constituted total lack of movement in the limb. This
scale of scoring was proven to be parallel to the NSS (neurological
severity score). Follow-up was performed blindly on a daily basis
by two separate observers. This type of follow up allows tracking
the decline of motor performance of animals in a precise manner.
The object recognition test (Bevins and Besheer, 2006) was
used as a measure for hippocampal dependent memory. The test
was carried out on 5–7 wt mice and 4–7 TgMHu2ME199K/KO
mice at each time point (ages 2, 4, 6, and 10 months). Data are
presented as fraction of time the animal spent actively exploring
the new object from total time of object exploration.
Histopathology
At each time point (ages 2, 4, 6, and 10 months), 5–7 mice
per group (WT and TgMHu2ME199K/KO) were sacrificed for
histopathological evaluation.Mice were anesthetized with a lethal
dose of pentobarbital and brains were perfused via the ascending
aorta with ice-cold PBS followed by cold 4% paraformaldehyde.
Tissues were deep-frozen in liquid nitrogen. Serial 10µMcoronal
sections were made. Immunofluorescent staining for mouse anti-
NeuN (Millipore) and rabbit anti-synaptophysin (Cell-Marque)
were performed, followed by incubation with Alexa-fluor555
goat anti-mouse IgG and Alexa-fluor555 goat anti-rabbit IgG
respectively, as previously described (Fainstein et al., 2013).
Nuclear counterstain was performed using DAPI (Vectashield).
Analysis was performed on each hemisphere in four brain
sections per mouse per staining, as detailed below.
Quantification of Cortical Cell Density
To measure cortical cell density, sections taken from 2, 4, 6,
and 10 month-old WT and TgMHu2ME199K/KO mice were
evaluated. Eight microscopic images of Dapi-stained nuclei were
obtained in a blinded manner from each brain section of the
cortical hemispheres in × 20 magnification. Each mouse brain
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was evaluated in coronal sections at the level of Bregma = 0.00
± 0.1mm. Two adjacent fields midway between pial lining and
corpus callosum at Bregma L = 1.0mm were counted from
each hemisphere (4 sections, 4 fields per section). Computerized
quantification of nuclei was performed using ImageJ (Process:
Binary : Watershed : Analyze Particles), using a size-based
threshold. An average value was calculated per animal, followed
by calculation of the group (± SEM) average values. Nuclear
counts for 2-months old wild-type mice were defined as baseline
(100%) for comparison.
Quantification of Cortical Neuronal and
Synaptic Density
To measure neuronal cell density in the cortex, sections
taken from 2- and 10- month old WT (n = 5) and
TgMHu2ME199K/KO (n = 5–7) mice at Bregma = 0.00
± 0.1mm were stained for NeuN and counted manually in
a blinded manner adhering to stereological principles. Two
adjacent x20 fields midway between the pial lining and the
corpus callosum at Bregma L = 1.0mm were counted from
each hemisphere (4 sections, 4 fields per section). Average
count in 2-months old wild-type mice was considered as
baseline of 100% for comparison. In order to estimate the
synaptic density in the cortex, 2- and 10- months old WT
and TgMHu2ME199K/KO mice at Bregma = 0.00 ± 0.1mm
were stained for synaptophysin. Two microscopic images were
obtained at the same position as for Neun quantification, at
a magnification of x40 and identical camera exposure from
each hemisphere (4 sections, 4 fields per section). Computerized
analysis was performed for the fraction of synaptophysin-stained
area from total area of the image. Synaptic density in the cortex
of 2-month old wild-type mice was regarded as baseline 100%
for comparison. Both NeuN and synaptophysin were calculated
as average values per mouse, followed by calculation of group
average.
Quantification of Hippocampal Cells
DAPI stained nuclei were counted manually in the CA1
and CA3 hippocampal regions in order to obtain a
quantitative assessment of neuron number. Counting
was performed on each hemisphere, on four sections per
brain (8 fields per region, per brain). Average values were
calculated for each mouse, followed by calculation of group
average.
Quantification of Neurogenesis
For identifying proliferating brain cells (neurogenesis), WT
and TgMHu2ME199K/KO mice of different age groups were
injected intraperitoneally with bromodeoxyuridine (BrdU,
Sigma-Aldrich, 50µg/g body weight) for 7 consecutive days
prior to sacrifice. Immunofluorescent staining for BrdU (rat α-
BrdU, Serotec) was performed as previously described (Fainstein
et al., 2013). The total number of BrdU-stained nuclei per
10µm thick section residing within the anatomic region of
the sub-ventricular / sub-ependymal zone (SVZ - SEZ) was
counted manually at magnification of x20 at sections taken
from Bregma = 0.00 ± 0.1mm. For identifying hippocampal
neurogenesis, BrdU-stained nuclei were counted manually in
the sub-granular zone of the dentate gyrus of sections taken
from Bregma = −2.0mm. Average values from 4 sections were
calculated for each mouse, followed by calculation of group
average.
Statistical Analyses
TgMHu2ME199K/KO mice were compared to their ages-
matched wild-type C57BL/6 control group using the
nonparametric Mann-Whitney test.
RESULTS
Progressive Neurological Impairment in
E200K Mice
TgMHu2ME199K/KO mice began to show hind limb weakness
at age 4–6 months, followed by progressive neurological
deterioration. At the age of 10 months mice exhibited significant
(p = 0.001) hind limb weakness (Figure 1A). PrPC aggregates,
the disease hallmark, were marginally detected in the cortex of
2 month-old mice, while considerable load of aggregates was
spotted at 10 months of age (Figures 1B,C).
FIGURE 1 | Progressive neurological impairment in E200K mice.
TgMHu2ME199K/KO mice showed progressive neurological disability
becoming apparent around age 6 month. Mice developed progressive hind leg
weakness, as observed at age 10 months (A). PrPC aggregates are barely
detected in the cortex of 2-month old TgMHu2ME199K/KO mice (B) and
highly prevalent in the cortex of 10-month old TgMHu2ME199K/KO mice (C).
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Age-Related Cortical Neurodegeneration
in E200K Mice
In light of progressive neurological disability, we examined
whether there is a neurodegenerative process in the
cortex of TgMHu2ME199K/KO mice. First, we performed
computerized quantification of cell density (by number of
cell nuclei) in the cortex at ages 2, 4, 6, and 10 months. No
difference in cortical cell density of TgMHu2ME199K/KO
mice as compared to wild-type mice was detected
(Figure 2).
We therefore examined whether there is a selective
degenerative process affecting predominantly cortical neurons.
We quantified the density of NeuN+ neurons in the cortex
(Figures 3A–E). At 10 months, there was a physiologic age-
related 23.3% loss of cortical neurons in wild-type mice. In
TgMHu2ME199K/KO mice, cortical neuron density was similar
at 2 months, but declined by 48.5% at 10 months, significantly
lower than wild-type mice (p= 0.04648). In view of the neuronal
loss, we examined synaptic density by computerized analysis
of synaptophysin immunostaining (Figures 3F–J). At age 2
months, there was no difference in synaptic density between
TgMHu2ME199K/KO and wild-type mice. At 10 months,
synaptic density declined by 25% in wild-type mice and by
59% in TgMHu2ME199K/KO mice (p = 0.004). Thus, synaptic
density declines in E200K mice in a manner comparable to loss
of neurons.
In conclusion, TgMHu2ME199K/KO mice exhibited cortical
neurodegeneration.
Age-Related Decline in Neurogenesis in
the Sub-ventricular / Sub-ependymal Zone
in TgMHu2ME199K/KO Mice
We further examined the rate of neurogenesis in the sub-
ventricular / sub-ependymal zone (SVZ - SEZ) of wild-type and
TgMHu2ME199K/KO mice. Specifically, we quantified BrdU
incorporation at the level of Bregma 0. There was an age-related
physiological decline in neurogenesis in wild-type mice. The
number of BrdU+ cells at 6 months showed a 27% decline and
dropped further at 10 months, by 39% (p = 0.02 as compared to
2 months) respectively, from the baseline level (Figure 4A).
The rate of neurogenesis was comparable in
TgMHu2ME199K/KO and wild-type mice at 2 months
(Figures 4B,C). However, neurogenesis declined to
a significantly lower rate of BrdU incorporation in
TgMHu2ME199K/KO mice as compared to wild-type at 6
and 10 months (Figures 4D,E). The number of BrdU+ cells
decreased by 40 and 76% at age 6 and 10 months respectively
(p = 0.01 and p = 0.06 respectively). In conclusion, there is
FIGURE 2 | Cortical cell density in TgMHu2ME199K/KO and wild-type mice. Low power field images showing the overall nuclear density in the cortex of 2
month- (A- wild-type, B- TgMHu2ME199K/KO mice), and 10 month-old wild-type and TgMHu2ME199K/KO mice (C,D, respectively). Quantification of nuclear density
was performed on high power field images according to the scheme shown in (E). Quantification did not show age-related changes, and there was no difference
between the two experimental groups throughout the follow-up period (F).
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FIGURE 3 | Age-dependent cortical neuronal and synaptic loss in TgMHu2ME199K/KO mice. Low power field images showing the overall density of cortical
NeuN+ neurons (A–D) and Synaptophysin (F–I) in 2 month- and 10 month-old wild-type and TgMHu2ME199K/KO mice. Quantification was performed on high
power field images according to the scheme shown in Figure 2E. No difference was observed in the number of NeuN+ cells between the groups at 2 month of age
(A,C,E). WT mice exhibited physiological, age related (A,B,E) 23.3% decrease in cortical NeuN+ cells (p = 0.015). TgMHu2ME199K/KO mice exhibited 53% (p =
0.046) reduction in cortical NeuN+ cells (C–E) at the age of 10 months. Analysis of the synaptic density, revealed similar findings. There was no difference between
TgMHu2ME199K/KO and WT mice at 2 months of age. There was a physiological 21% decrease in synaptic density in WT mice at 10 months (p = 0.02, F,G,J)
versus 59% (H,I,J) decrease in TgMHu2ME199K/KO mice (p = 0.004).
significant age-related decline in SVZ - SEZ neurogenesis as
compared to physiologic ageing.
Age-Related Memory Impairment in
TgMHu2ME199K/KO Mice
In order to examine whether TgMHu2ME199K/KO transgenic
mice also develop age-related memory impairment, they were
examined at ages 2–10 months using the object recognition
test (Bevins and Besheer, 2006; Figure 5). Their performance
was compared to wild-type mice. There was no difference in
performance at ages 2 and 4 months. A trend of decline was
noted at 6 months of age, and at 10months there was statistically-
significant memory impairment in TgMHu2ME199K/KO mice
(p= 0.01).
Age-Related Degeneration of the
Hippocampus in TgMHu2ME199K/KO Mice
We quantified neuronal cells in the CA1 and CA3 regions
at several time points (Figure 6). In wild-type mice, peak
counts of neurons were found at 4 months, with a mild
decline at ages 6 and 10 months (Figure 6). At ages 2 and 4
months there was no difference in neuronal counts between
TgMHu2ME199K/KO and wild-type mice. A significant 13%
decrease in number of neurons was observed in the CA1 region
of TgMHu2ME199K/KO mice as compared to wild-type at 6
months (p = 0.004), and 16% decline at 10 months (p =
0.015). In the CA3 region, a 19% decrease was measured at
the age of 10 months with borderline significance (p = 0.03).
Thus, TgMHu2ME199K/KO mice exhibit an accelerated loss
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FIGURE 4 | Age related decline in neurogenesis in sub-ventricular /
sub-ependymal zone in TgMHu2ME199K/KO mice. BrdU incorporating
cells were quantified in the sub-ventricular / sub-ependymal zone. Similar
neurogenesis rates were detected in young 2- and 4-month old WT and
TgMHu2ME199K/KO mice in the SVZ / SEZ. However, at 6 and 10 months of
age, there was a significant reduction in neurogenesis in TgMHu2ME199K/KO
versus WT mice (P = 0.01 and P = 0.06 respectively) in both areas (A).
Representative images show neurogenesis in 2 month-old wild-type and
TgMHu2ME199K/KO mice (B,C), and in 10 month-old mice (D,E,
respectively).
of hippocampal neurons as compared to physiologic aging of
wild-type mice.
Increased Hippocampal Neurogenesis in
E200K Mice
The generation of new neurons in the sub-granular zone of
the dentate gyrus (Lennington et al., 2003) occurs throughout
life, and plays an important role in memory functions (Snyder
et al., 2005). We therefore examined the rate of neurogenesis in
the dentate gyrus of TgMHu2ME199K/KO and wild-type mice
at various ages. There was a physiologic decline in the rate
of proliferation (indicated by uptake of BrdU) of subgranular-
zone cells in wild-type mice (Figure 7). At age 2 months, there
were 1.73-fold more BrdU+ cells in TgMHu2ME199K/KOmice,
as compared to wild-type mice (p = 0.03). At ages 4 and 6
months there were 1.71- (p = 0.054) and 2.13 = (p = 0.07)
fold more BrdU+ cells in the TgMHu2ME199K/KO mice as
compared to wild-type. At age 10 months, neurogenesis had
declined in both groups, by 75 and 85%, respectively, from that
of 2months, without significant difference betweenwild-type and
TgMHu2ME199K/KO mice.
FIGURE 5 | Age-related memory impairment in TgMHu2ME199K/KO
mice. No difference was detected in the performance of 2 and 4 month-old
TgMHu2ME199K/KO and WT mice in the object recognition test, a
hippocampal-dependent memory assessment. However, at 6 months of age a
trend (p = 0.06) toward poorer performance was noted in
TgMHu2ME199K/KO mice. Ten month-old WT mice performed significantly
better than TgMHu2ME199K/KO age-matched mice (p = 0.01).
In conclusion, TgMHu2ME199K/KO mice exhibited
memory impairment and loss of hippocampal volume as early
as 6 months. These mice exhibited increased hippocampal
neurogenesis initially, which declined thereafter and did not
compensate for the neuronal death.
DISCUSSION
A Need for Animal Models of
Neurodegeneration
Neurodegenerative diseases represent one of the most important
causes of morbidity and mortality in the aging population. The
common feature of the various diseases is the progressive loss
of brain neurons. To date, there are no available treatments to
cure or even slow down the progression of neurodegeneration.
Importantly, at the time of clinical diagnosis, there is already
advanced and irreversible brain atrophy. Ideally, the optimal
therapeutic approach would entail early, pre-symptomatic
intervention with medications that provide wide protection
of brain cells against the (common) pathogenic mechanisms
that cause neurodegeneration. When addressing illness in
the symptomatic stages, there is also a need for developing
regenerative therapies. A major limitation in studying the
mechanisms by which pathogenic events lead to brain atrophy
and in developing neuroprotective and regenerative therapies
is the critical shortage in animal models which display a
neurodegenerative process. For example, this drawback is seen
in most transgenic animal models of familial Alzheimer’s disease,
which exhibit typical pathologic features, including widespread
deposition of β-amyloid plaques but without associated neuronal
loss (Oddo et al., 2003a,b; Savonenko et al., 2005; Radde
et al., 2006). Furthermore, memory impairment in the double-
transgenic animal model of Alzheimer’s disease is independent
of hippocampal neuronal volume, and is completely reversed by
inhibiting innate immune cytokines, namely interleukin-1(Ben-
Menachem-Zidon et al., 2014), and TNFα (Tweedie et al., 2012).
Even the commonly-used animal model of familial Alzheimer’s
disease, carrying a cassette of 5 mutated human genes (the
5XFAD mouse) that has been reported to express β-amyloid
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FIGURE 6 | Age-related degeneration of the hippocampus in TgMHu2ME199K/KO mice. No difference was observed in the number of CA1 cells in the
hippocampus of young 2 and 4 months WT and TgMHu2ME199K/KO mice (upper left panel). Progressive reduction in the number of CA1 cells was observed starting
at 6 months of age and further at 10 months of age (Upper right panel, p = 0.004 and p = 0.015, respectively). In the CA3 hippocampal area (lower panel) there was
a significant decline (P = 0.03) in cell number in TgMHu2ME199K/KO versus WT mice at 10 month of age.
plaques as early as age 2 months and memory impairment at 4
months, exhibits only limited neuronal loss, observed mainly in
cortical layer 5 and subiculum of the hippocampus at 9 months
(Oakley et al., 2006). Although, local Aβ42 deposition was
elegantly shown to correlate with apoptotic activity and neuronal
loss in this brain region of 5XFAD mice (Eimer and Vassar,
2013), a major objective remains to develop animal models which
display progressive and substantial loss of brain neurons which
precedes cognitive decline.
TgMHu2ME199K/KO Mice Serve As a
Model for Neurodegenerative Diseases
The overlapping features of prion diseases and other
neurodegenerative diseases highlight their potential to serve
as a model for studying certain aspects of neurodegeneration
and neuroprotection. TgMHu2ME199K/KO mice serve as an
animal model for genetic prion disease, carrying the mutated
human gene for the prion protein. Given the progressive
decline in motor performance in TgMHu2ME199K/KO
mice, we performed longitudinal characterization of the
pathologic features of brain atrophy in these mice as compared
to wild-type mice. This study presents for the first time
histopathological evidence for a neurodegenerative process in
transgenic TgMHu2ME199K/KO mice, exhibiting progressive
loss of cortical and hippocampal neurons. This started at a
pre-clinical age of 4–6 months, followed by memory impairment,
which started after 6 months. The longitudinal study revealed the
dynamics of the neurodegenerative process, and indicated the
existence of an accelerated process of neuronal loss as compared
to normal physiologic aging in wild-type animals. Figure 8
summarizes the clinical and pathological features of this animal
model. Importantly, it shows the temporal correlation between
the neurodegenerative pathology and development of clinical
impairments.
Mechanisms of Neurodegeneration Which
Can be Studied in TgMHu2ME199K/KO
Mice
Several mechanisms of neuronal injury are common to multiple
neurodegenerative diseases. For example, the role of oxidative
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stress by reactive oxygen species (Van Everbroeck et al., 2004)
and microglial toxicity (Brown, 2001; Amor et al., 2010) has
been shown in prion diseases, as well as in Alzheimer’s disease
(Rapic et al., 2013; Heneka et al., 2015; Matsumura et al.,
2015), Parkinson’s disease (Aras et al., 2014; Borrajo et al.,
2014; Kim et al., 2015) and Huntington’s disease (Crotti et al.,
2014; Rotblat et al., 2014). Specifically, early oxidative stress
causing lipid peroxidation is linked to propagation of pathologic
prion protein accumulation and to typical neuropathological
changes in prion disease (Brazier et al., 2006). Similarly, oxidation
FIGURE 7 | Increased hippocampal neurogenesis in E200K mice. There
was progressive physiological decline in hippocampal neurogenesis with age.
There was a higher number of BrdU incorporating cells in the subgranular zone
of the dentate gyrus in TgMHu2ME199K/KO mice as compared to wild-type
mice up to the age of 6 months (p = 0.07). At 10 months of age there was no
difference in hippocampal neurogenesis between TgMHu2ME199K/KO and
WT mice.
of nucleic acids, proteins and lipids are an early pathologic
change in Alzheimer’s disease (Nunomura et al., 2006). Also, the
accumulation of prion protein is associated with activation of
microglia, leading to neurotoxic injury and gliosis (Brown, 2001;
Riemer et al., 2009). Similarly, activated microglia are involved in
the pathogenesis of Alzheimer’s disease, and β-amyloid toxicity is
strongly increased by the presence of microglia (Qin et al., 2002).
Therefore, we suggest that the transgenic TgMHu2ME199K/KO
model can serve as the basis for developing neuroprotective
and regenerative therapies that target the common mechanisms
of injury in neurodegenerative diseases. Indeed, our group
has recently shown the protective properties of anti-oxidant
therapy with nanoparticles of punicic acid emulsions in the
TgMHu2ME199K/KO mouse (Mizrahi et al., 2014).
This study shows decreased neurogenesis in the
subependymal / subventricular zone of TgMHu2ME199K/KO
mice at age of 6 months. The prion protein is expressed in
non-proliferating cells in the SVZ (Steele et al., 2006) and
inhibits the differentiation of neural precursors (Relaño-Ginès
et al., 2013). Interestingly, there was increased neurogenesis
in the subgranular zone of the dentate gyrus up to age 6
months, and then a decline to the low level of neurogenesis
in physiologically aging mice. These findings confirm the
recent report on increased hippocampal neurogenesis in the
infective form of prion disease (Gomez-Nicola et al., 2014). In
the wider perspective of neurodegenerative diseases, animal
models of familial Alzheimer’s disease more often exhibit
decreased hippocampal neurogenesis (Haughey et al., 2002;
Rodríguez et al., 2008; Demars et al., 2010), although normal
or even increased proliferative response to neurogenic stimuli
has been observed (Mirochnic et al., 2009; Perry et al., 2012).
FIGURE 8 | A temporal flow chart of clinical and pathological manifestation in TgMHu2ME199K/KO model. The pre-clinical stage of the disease starting
from 3 months of age is characterized by PK resistant PrP accumulation. Subsequently, at 5–6 months of age first motor deficits are revealed. As disease progresses
gliosis, cortical and hippocampal neuro-degeneration, decreased SVZ-SEZ neurogenesis and memory deficits are detected. In addition, increased hippocampal
neurogenesis identified in young TgMHu2ME199K/KO mice diminishes with age. The clinical disability and the pathological aberrations continue to deteriorate with
disease progression.
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Several studies of mouse lines representing familial Alzheimer
disease, mostly overexpression of APP, showed increased
hippocampal neurogenesis (Jin et al., 2004; Chuang, 2010).
A pathological study of human Alzheimer’s disease brain
specimens found a reduced number of hippocampal stem cells
with increased proliferation (Perry et al., 2012). Therefore, our
findings in TgMHu2ME199K/KO mice may further represent
other neurodegenerative diseases. There is a need to further
characterize the dynamics of neurogenesis in prion diseases, and
whether the inability of increased subgranular zone neurogenesis
to compensate for hippocampal neuronal loss is the result of
blocked differentiation or increased cell death.
In conclusion, transgenic TgMHu2ME199K/KOmice serve as
a model of chronic neurodegenerative disease. This model can
serve in studying the role of common disease mechanisms which
promote neurodegeneration and in testing neuroprotective and
pro-regenerative agents.
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